Compare KYN & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KYN | BCRX |
|---|---|---|
| Founded | 2004 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.3B |
| IPO Year | N/A | 1995 |
| Metric | KYN | BCRX |
|---|---|---|
| Price | $14.41 | $9.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $20.82 |
| AVG Volume (30 Days) | 461.1K | ★ 4.3M |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 8.99% | N/A |
| EPS Growth | N/A | ★ 381.40 |
| EPS | ★ 0.71 | N/A |
| Revenue | N/A | ★ $25,186,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.55 |
| P/E Ratio | $20.32 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.31 | $6.00 |
| 52 Week High | $14.69 | $11.31 |
| Indicator | KYN | BCRX |
|---|---|---|
| Relative Strength Index (RSI) | 61.99 | 48.90 |
| Support Level | $13.65 | $8.73 |
| Resistance Level | $14.69 | $9.40 |
| Average True Range (ATR) | 0.25 | 0.48 |
| MACD | 0.07 | 0.03 |
| Stochastic Oscillator | 91.58 | 59.95 |
Kayne Anderson Energy Infrastructure Fund, Inc is a non-diversified, closed-end fund. Its investment objective is to provide a high after-tax total return with an emphasis on making cash distributions to the stockholder. The Company invests in various sectors, which include midstream energy companies, renewable infrastructure companies, and utility companies. The company seeks to achieve its objectives by investing a majority of its total assets in the securities of Energy Infrastructure companies.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.